Buy the dip in American Express shares, Wells Fargo says
Wells Fargo maintained its overweight rating on AXP in the wake of the fallout from the failure of Silicon Valley Bank. It also repeated a $200 price target.
Barclays upgrades Match shares, says Tinder parent is now a value stock
Barclays upgraded Match shares to overweight from equal weight. The firm maintained its price target of $52, implying 49.5% upside from Monday’s close price.
Deutsche Bank says Charles Schwab liquidity risks are overblown, sticks with buy rating
Charles Schwab shares were hard-hit by the selloff of financial firms’ stocks following the SVB failure.
California braces for ‘catastrophic’ floods as East and West coasts face ‘double whammy’ of storms
Storm-battered California is facing another strong Atmospheric River Event as a powerful nor’easter was already disrupting travel early Tuesday in the Northeast, forecasters said.
Wells Fargo says buy this regional bank stock that has been ‘thrown out with the bathwater,’ sees nearly 150% upside
The firm reiterated its overweight rating on the stock, while lowering its price target to $65 from $90. Still, the new price target implies 148.9% upside.
Federal judge shares date of abortion pill hearing after media outlets criticize him for secrecy
A coalition of physicians who oppose abortion asked the judge in November to order the FDA to withdraw its approval of the abortion pill mifepristone.
McConnell discharged from the hospital after receiving treatment for a concussion
Senate Minority Leader Mitch McConnell sustained a concussion and a “minor rib fracture” in a fall last week, his office said.
Veterans Health Administration will cover Alzheimer’s treatment Leqembi, Eisai says
Veterans with early Alzheimer’s who meet certain VHA criteria can get the treatment covered, according to drugmaker Eisai.
Moderna shares pop 7% after Cowen upgrades stock, saying it ‘will be a leader’ in RSV vaccines
Moderna shares closed nearly 7% after TD Cowen upgraded the stock, saying the company will “be a leader” in the RSV vaccine market.
GitLab loses one-third of its value after software company issues weak revenue forecast
GitLab posted 58% revenue growth in the latest quarter, but its guidance for fiscal 2024 missed analysts’ estimates.
